Gynecologic Oncology Group (GOG-USA) Trials in Ovarian Cancer
In the United States, the Gynecologic Oncology Group (GOG) has been the leading clinical trial organization for women with gynecologic cancers. Recently, GOG has established collaborations with other clinical trials groups throughout the world to facilitate the rapid completion of large, randomized, controlled trials in women with ovarian cancer.
In ovarian cancer, GOG has performed a series of clinical trials in three distinct subsets of women with markedly different prognostic factors: early stage (FIGO I and II), advanced stage (FIGO III) with optimally resected disease (no residual tumor nodule greater than 1 cm), and advanced stage (FIGO III and IV) with suboptimal disease. GOG clinical trials in ovarian cancer have evaluated different strategies in these three distinct patient groups, including adjuvant therapy, maintenance therapy, consolidation approaches, interval debulking surgery, the role of second-look operations, new chemotherapeutic regimens, and the role of intraperitoneal (IP) chemotherapy. More recently, GOG has been evaluating the role of biological therapies (molecular-targeted treatment), either as single-agent treatment or in combination with chemotherapy.
KeywordsOvarian Cancer Clin Oncol Epithelial Ovarian Cancer Advanced Ovarian Cancer Epithelial Ovarian Carcinoma
Unable to display preview. Download preview PDF.